Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

SML3069

Sigma-Aldrich

NVP-2

≥98% (HPLC)

Sinónimos:

4-[[[5′-Chloro-2′-[[trans-4-[[(1R)-2-methoxy-1-methylethyl]amino]cyclohexyl]amino][2,4′-bipyridin]-6-yl]amino]methyl]tetrahydro-2H-pyran-4-carbonitrile, NVP2

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C27H37ClN6O2
Número de CAS:
1263373-43-8
Peso molecular:
513.07
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

C[C@H](COC)N[C@@H]1CC[C@@H](NC2=NC=C(Cl)C(C3=NC(NCC4(CCOCC4)[N+]#[C-])=CC=C3)=C2)CC1

Biochem/physiol Actions

NVP-2 is an ATP-competitive, highly potent and selective cyclin-dependent kinase CDK9 inhibitor (human Cdk9/CycT1 IC50 = 0.3 nM with 6 μM ATP; DYRK1B IC50 = 350 nM; CDK7 IC50 >10 ?M; 0-63% inhibition of 366 other kinases at 1 μM, including CDK2/3/4/5/8). NVP-2 inhibits RNA Pol II-mediated transcription by blocking Cdk9-dependent RNA Pol II CTD phosphorylation (250 nM for 1-24 hrs; MOLT4 cells), displaying higher apoptosis-inducing and antiproliferation efficacy than the CDK2/7/9 inhibitor SNS-032 (BMS-387032) in leukemia cultures (MOLT4 IC50 = 9 nM/NVP-2 vs. 173 nM/SNS-032).

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Phillip Wright et al.
Archives of toxicology, 93(3), 659-671 (2019-01-09)
Cyclin-dependent kinases (CDKs) are a family of kinases associated predominantly with cell cycle control, making CDK inhibitors interesting candidates for anti-cancer therapeutics. However, retinal toxicity (loss of photoreceptors) has been associated with CDK inhibitors, including the pan-CDK inhibitor AG-012896. The
Matthias Muhar et al.
Science (New York, N.Y.), 360(6390), 800-805 (2018-04-07)
Defining direct targets of transcription factors and regulatory pathways is key to understanding their roles in physiology and disease. We combined SLAM-seq [thiol(SH)-linked alkylation for the metabolic sequencing of RNA], a method for direct quantification of newly synthesized messenger RNAs
Yang Gao et al.
Cell chemical biology, 25(2), 135-142 (2017-12-26)
Irreversible inhibition of transcriptional cyclin-dependent kinases (CDKs) provides a therapeutic strategy for cancers that rely on aberrant transcription; however, lack of understanding of resistance mechanisms to these agents will likely impede their clinical evolution. Here, we demonstrate upregulation of multidrug
Georg E Winter et al.
Molecular cell, 67(1), 5-18 (2017-07-05)
Processive elongation of RNA Polymerase II from a proximal promoter paused state is a rate-limiting event in human gene control. A small number of regulatory factors influence transcription elongation on a global scale. Prior research using small-molecule BET bromodomain inhibitors
Calla M Olson et al.
Nature chemical biology, 14(2), 163-170 (2017-12-19)
Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico